• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    LifeStance Stock Gains Focus After Earnings Profit And Depression Treatment Results

    Simply Wall St·11/05/2026 13:35:36
    Listen to the news
    • LifeStance Health Group reported third quarter 2026 sales of US$455.86 million and net income of US$22.39 million, with nine‑month net income of US$60.24 million and positive earnings per share from continuing operations.
    • The company also highlighted clinical results from expanded treatment resistant depression services, with esketamine and TMS associated with reductions in symptoms and suicidal ideation across more than 600 analyzed patients.
    • We will now explore how LifeStance Health Group's reported profitability and treatment resistant depression outcomes could influence the existing investment narrative.

    Scan beyond LifeStance Health Group and size up other mental health and healthcare operators on our curated list of 38 healthcare AI stocks as this segment keeps drawing investor attention.

    LifeStance Health Group Investment Narrative Recap

    To own LifeStance Health Group, you need to believe the mental health platform can keep scaling clinicians, visit volumes and specialty services while converting that growth into sturdier margins and cash generation. The latest quarter, with US$455.86 million in sales and US$22.39 million in net income, shows the model currently supports profitable operations.

    In the near term, the key catalyst is whether management can sustain operating efficiency after this step up in profitability, given a history of thin free cash flow and low returns on equity. The biggest risk remains execution in a competitive behavioral health market that includes large, well funded players with deeper pockets.

    The treatment resistant depression update around esketamine and TMS matters directly to that execution story. Management reported clinically meaningful symptom reductions in 74% of esketamine patients and 61% of TMS patients across more than 600 cases, along with sharp reductions in reported suicidal ideation on PHQ 9 scores.

    Those clinical outcomes give LifeStance Health Group more evidence behind higher acuity offerings that can support its specialty services catalyst, where expectations already point to a richer service mix. The operational test now is disciplined rollout, clinician capacity and payer relationships, since missteps in these areas could add cost complexity or invite stronger competitive responses.

    LifeStance Health Group's current analyst narrative points to US$2.4b in revenue and US$163.8 million in earnings by 2029, based on 14.8% yearly revenue growth and an earnings increase of roughly US$113.2 million from US$50.6 million today.

    Uncover why LifeStance Health Group's fair value indicates that it is roughly in line with its current price.

    NasdaqGS:LFST 1-Year Stock Price Chart
    NasdaqGS:LFST 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate take puts LifeStance Health Group’s treatment resistant depression push at the center of a much more optimistic story. Before this earnings and outcomes update, the most bullish analysts were already penciling in about US$2.6b of revenue and US$184.5 million of earnings by 2029. You can now ask whether these new results justify exploring that upside case or if expectations need a reset.

    Explore 2 other LifeStance Health Group fair value estimates, including one that suggests as much as 6% upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Ideas Beyond LifeStance Health Group?

    If you want to balance your view on LifeStance Health Group with fresh opportunities, the Simply Wall St Screener can help you quickly surface stocks that fit very different goals, from value hunting to stability or income.

    • For investors hunting for value with quality in mind, start by scanning a curated 35 high quality undervalued stocks that blend strong fundamentals with prices that may not fully reflect them.
    • If capital protection and smoother returns matter most to you, focus on a 31 resilient stocks with low risk scores that screens for resilient businesses with lower risk scores.
    • Income focused investors looking to reinforce their yield stream can review a curated set of 5 dividend fortresses that pair higher payouts with business fundamentals.